News

The goal of the collaboration is to accelerate Purdue’s Nav1.7 sodium ion channel drug candidates utilizing AnaBios’ Phase-X discovery platform to develop treatments for chronic pain. Under the terms

Data from this study is expected to be announced in the first half of 2017.  MAT2501 is Matinas BioPharma’s orally-administered, encochleated formulation of the broad spectrum IV-only aminoglycoside

LOJUXTA, marketed as JUXTAPID in the United States, is currently approved by the European Commission as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low

The company submitted a new drug application (NDA) to the US Food and Drug Administration and a marketing authorisation application to the European Medicines Agency. Semaglutide works by stimulating insulin

Bosulif is an oral, once-daily, tyrosine kinase inhibitor, which inhibits the Bcr-Abl kinase that promotes CML. The BFORE study met its primary endpoint of major molecular response (MMR)

The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA. Amgen Research and Development executive vice president Sean E. Harper, M.D. said: "The

VONVENDI is an on-demand recombinant treatment for adults living with VWD and replaces von Willebrand factor (VWF), one of several types of proteins in the blood that are

Pfizer announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly

The company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). The company submitted its MAA in the US several weeks